EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma

Kohei Shitara iD, Manish A Shah iD, Florian Lordick, Eric Van Cutsem, David H Ilson, Samuel J Klempner, Yoon-Koo Kang, Sara Lonardi, Yi-Ping Hung, Kensei Yamaguchi, Peter Enzinger, Tomoko Nakajima und 9 weitere

New England Journal of Medicine · 26.09.2024 · 391 (12) · 1159-1162

DOI: 10.1056/nejmc2409512 ↗

Kurz gefasst

Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 26.09.2024. Verfasst von Kohei Shitara und 20 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Esophageal Neoplasms, Esophagogastric Junction, Stomach Neoplasms. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 3 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionStomach NeoplasmsHumansAntibodies, MonoclonalClinical Trials, Phase III as TopicProgression-Free SurvivalAntineoplastic Combined Chemotherapy ProtocolsRandomized Controlled Trials as TopicNauseaVomitingMaleFemaleYoung AdultAdultMiddle AgedAgedAged, 80 and overMulticenter Studies as Topic

Substanzen

Antibodies, Monoclonalzolbetuximab

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Weill Cornell Medical College, New York, NY.
  • University of Leipzig Medical Center, Leipzig, Germany.
  • University Hospitals Gasthuisberg, Leuven, Belgium.
  • Memorial Sloan Kettering Cancer Center, New York, NY.
  • Massachusetts General Cancer Center, Boston, MA.

ORCID-Profile: Kohei Shitara, Manish A Shah, Jaffer A Ajani

Förderung

  • NCI NIH HHS
  • Astellas Pharma

Zitieren

APA

Shitara, K., Shah, M. A., Lordick, F., Van Cutsem, E., Ilson, D. H., Klempner, S. J., Kang, Y. K., Lonardi, S., Hung, Y. P., Yamaguchi, K., Enzinger, P., Nakajima, T., Matsangou, M., Cao, Y., Li, R., Moran, D., Pophale, R., Oh, M., Ranganath, R., …, & Xu, R. H. (2024). Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. New England Journal of Medicine, 391(12), 1159-1162. https://doi.org/10.1056/nejmc2409512

Vancouver

Shitara K, Shah MA, Lordick F, Van Cutsem E, Ilson DH, Klempner SJ, et al. Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. New England Journal of Medicine. 2024;391(12):1159-1162. doi:10.1056/nejmc2409512

BibTeX
@article{Shitara2024,
  author = {Shitara, Kohei and Shah, Manish A and Lordick, Florian and Van Cutsem, Eric and Ilson, David H and Klempner, Samuel J and Kang, Yoon-Koo and Lonardi, Sara and Hung, Yi-Ping and Yamaguchi, Kensei and Enzinger, Peter and Nakajima, Tomoko and Matsangou, Maria and Cao, Ying and Li, Ran and Moran, Diarmuid and Pophale, Rupesh and Oh, Mok and Ranganath, Radhika and Ajani, Jaffer A and Xu, Rui-Hua},
  title = {Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {12},
  pages = {1159--1162},
  doi = {10.1056/nejmc2409512}
}
Kostenlos starten →